Please ensure Javascript is enabled for purposes of website accessibility

Galapagos and Gilead Sciences Post Successful Yet Disappointing Filgotinib Results

By Cory Renauer - May 21, 2020 at 11:20AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

In a phase 2b/3 study in ulcerative colitis, the drug candidate met its goals, but with results that didn't appear better than those of a potential competitor.

Gilead Sciences (GILD 1.48%) and its collaboration partner, Galapagos (GLPG 2.37%), reported somewhat disappointing news for their anti-inflammatory candidate, filgotinib. The potential blockbuster helped patients with ulcerative colitis achieve remission, but perhaps not as well as Rinvoq, a similar drug from AbbVie (ABBV 0.15%) currently approved to treat patients with rheumatoid arthritis.

Underwhelming data 

Ulcerative colitis patients who hadn't previously been treated with an injectable drug were significantly more likely to achieve remission with filgotinib than those given a placebo, but it looks like Gilead Sciences and Galapagos could have trouble competing with AbbVie for this population.

Confused businessperson.

Image source: Getty Images.

During a phase 2b study of Rinvoq, 10% of ulcerative colitis patients treated with 15 mg of the drug daily achieved remission compared to zero patients in the placebo group. Among a similar patient population, filgotinib helped 26.1% achieve remission compared to 15.3% of the placebo group.

Next steps?

Filgotinib and Rinvoq are both Janus kinase (JAK) inhibitors, a class of drugs associated with potentially lethal side effects experienced by an almost imperceptibly small number of clinical trial participants. At the moment, Rinvoq is approved to treat rheumatoid arthritis at a relatively limited 15 mg dosage despite appearing far more effective at higher concentrations.

If regulators take issue with the successful dosage of filgotinib for any reason, the drug's chances of approval for ulcerative colitis will fall much further. While filgotinib is arguably the safest member of the JAK inhibitor class, the lower of two doses tested didn't improve ulcerative colitis patients' chances of achieving remission.

Cory Renauer owns shares of Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$62.91 (1.48%) $0.92
Galapagos Stock Quote
$54.53 (2.37%) $1.26
AbbVie Inc. Stock Quote
AbbVie Inc.
$140.46 (0.15%) $0.21

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/10/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.